trending Market Intelligence /marketintelligence/en/news-insights/trending/pu3yquhz_fxcdubrbzkdbw2 content esgSubNav
In This List

US FDA records violations at Alkem's manufacturing plants in India, US

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA records violations at Alkem's manufacturing plants in India, US

Alkem Laboratories Ltd. said the U.S. Food and Drug Administration recorded 13 violations at its manufacturing facilities in India and the U.S.

The regulator issued a Form 483 following an inspection at the company's plants in Daman, India, and St. Louis.

A Form 483 is issued when investigators observe any conditions or practices that may have violated the Food Drug and Cosmetic Act and could later pose health hazards to consumers.

The company has already submitted a corrective and preventive action plan to the FDA for its U.S.-based facility.

Alkem plans to submit a response for the Indian facility in the future.